Related references
Note: Only part of the references are listed.Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
Marianna Puccini et al.
METABOLITES (2022)
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Piotr Peczek et al.
LIFE-BASEL (2021)
Pleiotropic Effects of PCSK-9 Inhibitors
Marcin Basiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
Gregory G. Schwartz et al.
CIRCULATION (2020)
Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
Jia Peng et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
Francesco Paciullo et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Oxidized low-density lipoprotein in inflammation-driven thrombosis
G. Obermayer et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia
Ye-Xuan Cao et al.
ATHEROSCLEROSIS (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Increased plasma thrombin potential is associated with stable coronary artery disease: An angiographically-controlled study
Federica Tosi et al.
THROMBOSIS RESEARCH (2017)
DIFFERENTIAL EXPRESSION OF PCSK9 MODULATES INFECTION, INFLAMMATION, AND COAGULATION IN A MURINE MODEL OF SEPSIS
Dhruva J. Dwivedi et al.
SHOCK (2016)
Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation
Amber B. Ouweneel et al.
VASCULAR PHARMACOLOGY (2016)
Factoring in Factor VIII With Acute Ischemic Stroke
James E. Siegler et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2015)
Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
Yan Zhang et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Thrombosis formation on atherosclerotic lesions and plaque rupture
L. Badimon et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Daniel Urban et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile
Nicola Martinelli et al.
BLOOD (2010)
From vulnerable plaque to atherothrombosis
T. Thim et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease
WB Kannel
LIPIDS (2005)
Pathobiology of atherosclerosis - a brief review
N Kher et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2004)
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes
R Krysiak et al.
DRUGS (2003)
Share Paper
